The background to the decision is that there have been different opinions about the company's future. By convening an Extraordinary General Meeting, it is up to the company's owners to decide on possible new Board members.

"We continue to evaluate possible alternatives for LIDDS and are actively working to find a solution that provides the best value for the company's shareholders. So far, our efforts have not led to the results we had hoped for. The evaluations have also meant that the Board has chosen to decline the proposals. As it has emerged that there are different views on the company's future, we believe that the composition of the Board of Directors shall be a matter for our owners," said Pontus Ottosson, Chairman of the Board of LIDDS.

Over the past 18 months, LIDDS has actively been working to find a potential partner for the company's leading asset Liproca Depot, as well as the broader project portfolio. Over the past year, the company has been in contact with over 200 companies, selected for their specific interest in oncology and urology, and has covered the entire spectrum of companies, from multinational pharmaceutical companies to smaller specialist companies. So far, most of these companies have chosen to decline the opportunity to in-license assets from LIDDS.

The Board of Directors is still hopeful to reach a solution that reflects the value of the company’s assets.